With all 3 business units contributing positive contribution margin, the Company expects to return to positive
EBITDA and operating cash generation in FY24.
For International, the Company is pursuing targeted investment and new manufacturing revenue streams. The
Company plans to continue to drive specialty and generic product sales including driving growth in NEXTSTELLIS®
in Australia and will continue to invest in a targeted manner in the Salisbury facility to improve our productivity
and capabilities - International alone showed growth by 10 m
Mayne Pharma sees strong sales growth in FY 2023, page-64
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.61 |
Change
-0.050(1.07%) |
Mkt cap ! $392.1M | |||
| Open | High | Low | Value | Volume |
| $4.63 | $4.70 | $4.55 | $667.6K | 144.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 171 | $4.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.63 | 171 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MYX (ASX) Chart |